istock-508496956cosmin4000
cosmin4000 / iStockphoto.com
27 September 2018Americas

IP and personalised medicine: a tailor-made approach

In 2017, the US Food and Drug Administration (FDA) approved a record 16 new personalised medicines, according to the “Personalized Medicine at FDA: 2017 Progress Report”. From 2014 to 2017, more than one in every four drugs the agency approved was a personalised medicine.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
5 May 2026   J&J’s Abiomed can proceed with its non-infringement defence despite potential future appellate reversal, in a week when both parties in the case were dealt wins and losses in their clash over Impella devices.
Americas
4 May 2026   LSIPR's senior reporter Marisa Woutersen speaks with Ben Doranz of Integral Molecular, fresh from the stage at LSPN Boston after speaking at a panel session on challenges in antibody patent protection.
Americas
1 May 2026   The Office of the US Trade Representative has placed the EU on its Watch List, outlining concerns about pharma legislation, GIs and digital copyright.